Strengthening Your COVID-19 Management Technique
Exercising Best Practices for Hospitalized Patients
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F, Bouscambert-Duchamp M, Hites M, et al. Lancet Infect Dis. 2022;22(2):209-221.
Long COVID risk and pre-COVID vaccination: an EHR-based cohort study from the RECOVER program.
Brannock MD, Chew RF, Preiss AJ, et al. Preprint. Posted online October 7, 2022. medRxiv. 2022:2022.10.06.22280795.
Persistent presence of spike protein and viral RNA in the circulation of individuals with post-acute sequelae of COVID-19.
Craddock V, Mahajan A, Krishnamachary B, et al. Preprint. Posted online August 9, 2022. medRxiv. 2022:2022.2008.2007.22278520.
Dexamethasone in hospitalized patients with Covid-19.
Horby P, Lim WS, Emberson JR, et al. N Engl J Med. 2021;384(8):693-704.
Immunopathogenesis and treatment of cytokine storm in COVID-19.
Kim JS, Lee JY, Yang JW, et al. Theranostics. 2021;11(1):316-329.
A review of COVID-19 in relation to metabolic syndrome: obesity, hypertension, diabetes, and dyslipidemia.
Makhoul E, Aklinski JL, Miller J, et al. Cureus. 2022;14(7):e27438.
Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of coronavirus disease 2019 (COVID-19) patients requiring supplemental O2 therapy: a prospective controlled nonrandomized study.
Marrone A, Nevola R, Sellitto A, et al. Clin Infect Dis. 2022;75(1):e403-e409.
Infliximab for treatment of adults hospitalized with moderate or severe Covid-19.
O’Halloran JA, Kedar E, Anstrom KJ, et al. Preprint. Posted online September 26, 2022. medRxiv. 2022:2022.2009.2022.22280245.
Hospitalization and mortality among Black patients and White patients with Covid-19.
Price-Haywood EG, Burton J, Fort D, et al. N Engl J Med. 2020;382(26):2534-2543.
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Lancet. 2021;397(10285):1637-1645.
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group. Lancet. 2022;400(10349):359-368.
The association of baseline plasma SARS-CoV-2 nucleocapsid antigen level and outcomes in patients hospitalized with COVID-19.
Rogers AJ, Wentworth D, Phillips A, et al. Ann Intern Med. 2022;175(10):1401-1410.
Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial.
Tomazini BM, Maia IS, Cavalcanti AB, et al. JAMA. 2020;324(13):1307-1316.
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q, Iketani S, Li Z, et al. Cell. 2023;186(2):279-286.
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
WHO Solidarity Trial Consortium. Lancet. 2022;399(10339):1941-1953.
Nirmatrelvir and the risk of post-acute sequelae of COVID-19.
Xie Y, Choi T, Al-Aly Z. Preprint. Posted online November 5, 2022. medRxiv. 2022:2022.2011.2003.22281783.
Clinical Practice Guidelines
COVID-19 Treatment Guidelines.
National Institutes of Health.
Clinical management of COVID-19: living guideline.
World Health Organization.
Clinician Resources
Trends in number of COVID-19 cases and deaths in the US reported to CDC, by state/territory.
Centers for Disease Control and Prevention.
Dexamethasone prescribing information.
US Food and Drug Administration (FDA).
Highlights of prescribing information: Veklury® (remdesivir).
FDA.
Actrema (tocilizumab) prescribing information.
Genentech.
Olumiant (baricitinib) prescribing information.
Lilly.
Strengthening Your COVID-19 Management Technique
Exercising Best Practices for Patients Hospitalized With COVID-19
| Faculty: | Eric S. Daar, MD; Jens Lundgren, MD, DMSc |
| Release: | 02/17/2023 |
| Expiration: | 02/17/2024 |
